Mylan Inc. has launched voriconazole tablets, an antifungal medication, under a previously announced settlement and license agreement with Pfizer Inc.


Mylan, Vfend, voriconazole tablets, generic version, Pfizer, Vfend tablets, antifungal medication, triazole antifungal agent, Mylan Pharmaceuticals, pharmaceuticals


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan introduces generic version of Vfend

February 15th, 2011

PITTSBURGH – Mylan Inc. has launched voriconazole tablets, an antifungal medication, under a previously announced settlement and license agreement with Pfizer Inc.

The company said Tuesday that its Mylan Pharmaceuticals Inc. subsidiary introduced  voriconazole tablets in strengths of 50 mg and 200 mg. The product is the generic version of Pfizer's Vfend tablets, a triazole antifungal agent.

Mylan noted that it was the first company to have filed a substantially complete abbreviated new drug application (ANDA) containing a Paragraph IV certification for voriconazole tablets and was awarded 180 days of marketing exclusivity.

According to Mylan, Vfend tablets had U.S. sales of approximately $186 million for the 12 months ended Dec. 31, 2010, based on IMS Health data.

Advertisement